IRVINE, Calif. - MRI Interventions, Inc. (OTCQB:MRIC) announced that neurosurgeons at UC San Diego Health System have utilized the ClearPoint(R) system's platform capabilities to facilitate three same-setting MRI-guided neurosurgical procedures for a single patient. The team, led by Clark C. Chen, MD, PhD, vice-chairman of Academic Affairs for the Division of Neurosurgery at UC San Diego School of Medicine, biopsied a patient's brain tumor, aspirated a fluid-filled section of the tumor, and ablated the tumor, all under real-time MRI guidance enabled by the ClearPoint system in the hospital's diagnostic MRI suite.

Utilizing conventional techniques, the three surgeries likely would

have been split between two or three different settings and required

the patient to be moved between the neuro OR and diagnostic MRI suite.

The ClearPoint system, however, enables placement of multiple devices

along the same trajectory, as well as facilitates intraoperative

adjustments with real-time visual verification to accommodate multiple

trajectories as necessary, all within a hospital's standard diagnostic

MRI scanner.

MRI Interventions Business Development Manager and clinical engineer

Geoffrey Bates attended the surgery. "We were very happy to see the

ClearPoint system's platform capabilities being utilized in a single

case," said Bates. "UC San Diego took a set of procedures that would

ordinarily be performed over multiple days and multiple rooms and

condensed them into the same setting. That means fewer hospital visits

for the patient and more efficient scheduling and workflow for the

surgical team."

Using the ClearPoint system for the biopsy, Dr. Chen was able to see

and select the tumor at its location within the brain, establish the

desired trajectory to the tumor with MRI Interventions' SmartFrame(R)

targeting device, and visualize the biopsy needle as it was inserted

into the desired region of the tumor, confirming with real-time MRI

that the sample was removed from the targeted location. Next, Dr. Chen

was able to adjust the trajectory in order to aspirate a fluid-filled

section of the tumor, monitoring the tumor's changing size and shape

under MRI guidance as the fluid was removed. Dr. Chen then utilized the

ClearPoint system to target the reduced tumor, visualize the placement

of a laser catheter as he inserted it into the tumor, and confirm

placement of the catheter at the desired location for ablation.

Finally, when intraprocedural MRI showed that a portion of the tumor

was irregularly shaped, he was able to once more adjust the SmartFrame

targeting device to reposition the catheter so that he could ablate the

final segment of the tumor.

The ClearPoint system is the only technology to enable

minimally-invasive neurosurgery under continuous MRI guidance. In

addition to brain biopsy and the placement of shunts and laser ablation

catheters, the ClearPoint system is also being utilized to place

electrodes in the brain.

About the ClearPoint system

The ClearPoint system is a navigation platform designed to allow

real-time, direct visualization during minimally-invasive neurosurgical

procedures. It is intended to provide stereotactic guidance for the

placement and operation of instruments or devices during planning and

operation of neurosurgical procedures within the MRI environment and in

conjunction with MR imaging. The ClearPoint system is intended as an

integral part of procedures that have traditionally used stereotactic

methodology, which procedures include biopsies and catheter and

electrode insertions. The ClearPoint system software works with MRI to

assist surgeons in planning a target and trajectory, and the

SmartFrame(R) targeting device enables the MRI-guided alignment and

insertion of surgical instruments.

About MRI Interventions, Inc.

Building on the imaging power of MRI, MRI Interventions is creating

innovative platforms for performing the next generation of minimally

invasive surgical procedures in the brain and heart. The company's

ClearPoint(R) system, which has received 510(k) clearance and is CE

marked, utilizes a hospital's existing diagnostic or intraoperative MRI

suite to enable a range of minimally invasive procedures in the brain.

In partnership with Siemens Healthcare, MRI Interventions is developing

the ClearTrace(R) system to enable MRI-guided catheter ablations to

treat cardiac arrhythmias, including atrial fibrillation. For more

information, please visit www.mriinterventions.com.

Forward-Looking Statements

Certain matters in this press release may constitute forward-looking

statements within the meaning of Section 27A of the Securities Act of

1933 and Section 21E of the Securities Exchange Act of 1934.

Forward-looking statements often can be identified by words such as

"anticipates," "believes," "could," "estimates," "expects," "intends,"

"may," "plans," "potential," "predicts," "projects," "should," "will,"

"would," or the negative of these words or other words of similar

meaning. Forward-looking statements by their nature address matters

that, to different degrees, are uncertain and involve risk.

Uncertainties and risks may cause MRI Interventions' actual results and

the timing of events to differ materially from those expressed in or

implied by MRI Interventions' forward-looking statements. Detailed

information on factors that could affect MRI Interventions' actual

results are described in MRI Interventions' filings with the Securities

and Exchange Commission, including, without limitation, the quarterly

report on Form 10-Q filed on August 11, 2014. Except as required by

law, MRI Interventions undertakes no obligation to publicly update or

revise any forward-looking statements contained in this press release

to reflect any change in MRI Interventions' expectations or any change

in events, conditions or circumstances on which any such statements are

based.